Ananda Developments PLC NHS SCOTLAND TO FUND MRX1 ENDOMETRIOSIS TRIAL (2739J)
August 15 2023 - 2:00AM
UK Regulatory
TIDMANA
RNS Number : 2739J
Ananda Developments PLC
15 August 2023
15 August 2023
ANANDA DEVELOPMENTS PLC
("Ananda" or the "Company")
NHS SCOTLAND TO FUND MRX1 ENDOMETRIOSIS TRIAL
Ananda Developments plc (AQSE: ANA), a company whose ambition is
to be a leading provider of cannabinoid-based medicines for the
treatment of chronic, complex inflammatory pain conditions, is
pleased to announce that the Chief Scientist Office ("CSO"), which
is part of the Scottish Government Health Directorate and is
responsible for funding research in NHS Scotland (NHS) is providing
the non-dilutive funding for the previously announced endometriosis
randomised controlled trial ("RCT") using Ananda's MRX1 sublingual
cannabidiol oil. The CSO is providing GBP300,000 to conduct the
trial using Ananda's patent pending MRX1 formulation and matching
placebo.
The endometriosis RCT will be conducted by Dr Lucy H R Whitaker
(BSc (Hons) MB ChB MSc MD MRCOG), NES CSO Clinical lecturer in
Obstetrics and Gynaecology at The University of Edinburgh. Dr
Whitaker is supported by Professor Andrew W Horne (PhD, FRCOG, FRCP
Edin, FRCSEd, FRSE), Professor of Gynaecology and Reproductive
Sciences at The University of Edinburgh. Prof Horne is also
Co-director of EXPPECT Edinburgh, Specialty Advisor to Scotland's
Chief Medical Officer for Obstetrics and Gynaecology,
President-elect of the World Endometriosis Society & Co-Editor
in chief of Reproduction and Fertility. The 100 endometriosis RCT
participants will take Ananda's patent pending MRX1 cannabidiol oil
or matching placebo.
Melissa Sturgess, CEO of Ananda, commented "Our objective is to
have MRX1 included by the NHS as an efficacious and cost-effective
treatment for pain associated with endometriosis. Getting NHS
funding for this trial using MRX1 is a clear statement of the
importance of endometriosis as a public health issue and we believe
clearly demonstrates the interest in the use cannabidiol as a
potential treatment for endometriosis and other complex chronic
inflammatory pain conditions by the UK's public health bodies . The
chronic, complex inflammatory pain market was recently estimated (
https://www.england.nhs.uk/blog/anthony-woolf/ ) to be worth at
least GBP5 billion per annum in the UK alone ."
For further information about the use of MRX1 in clinical trials
please contact nick.clarkson@mrxmedical.com and for all other MRX
enquiries, including for MRX1 to be prescribed by specialists,
please contact Jack@anandadevelopments.com
Further information on the trial:
TCS/22/28 - ENDOCAN-1: A Pilot Randomised Controlled Trial Of
The Efficacy Of A Cannabinoid Oral Tincture In The Management Of
Endometriosis-Associated Pain.
Background: Endometriosis (where cells similar to the
womb-lining are found elsewhere in the body) affects 190 million
women worldwide and may lead to debilitating pelvic pain.
Endometriosis pain symptoms can be managed medically by hormonal
drugs, but only one third of women feel that these are effective
and many experience side-effects. Cannabinoids are substances
extracted from cannabis and are promising treatments for pain
conditions like endometriosis.
Aim: We aim to investigate if a future large scale, UK-wide
trial to determine whether a cannabinoid can reduce
endometriosis-associated pain is possible.
Design and Methods: We will perform a pilot study, called
ENDOCAN-1, in two Scottish hospitals. We will recruit 100 women
with pelvic pain due to endometriosis. The women will be randomly
assigned to take an oral cannabinoid called cannabidiol (CBD) in a
tincture (liquid) or identical placebo for twelve weeks. Neither
the women, nor their medical team, will know what treatment they
are taking. Participants will be asked to complete questionnaires
about their symptoms. These will help to plan a future larger study
to determine whether CBD reduce endometriosis-associated pain and
provide value for money. We will also interview 20 women to find
out their feelings about participation and experiences with the
medication.
Dissemination: The results of the trial will be published in
medical journals, presented at medical conferences, and publicised
in summaries/infographics on social media platforms. The trial
results will also be made available to patients on the
Endometriosis UK website and social media.
To stay abreast of the latest developments at Ananda, we
encourage you to follow our social media channels which are:
-- Instagram: https://instagram.com/anandadevelopments?igshid=YmMyMTA2M2Y=
-- LinkedIn: https://www.linkedin.com/company/anadevelopments/
-- Twitter: https://twitter.com/anandaplc?s=21&t=9yeIC_xYCfzgDn7j26sfuA
-Ends-
The Directors of the Company accept responsibility for the
contents of this announcement.
ANANDA DEVELOPMENTS PLC +44 (0)7463 686 497
ir@anandadevelopments.com
Chief Executive Officer
Melissa Sturgess
Finance Director
Jeremy Sturgess-Smith
SP ANGEL CORPORATE FINANCE LLP +44 (0)20 3470 0470
Corporate Finance
Richard Morrison
Harry Davies-Ball
Corporate Broking
Abigail Wayne
Rob Rees
About Ananda Developments
Ananda is an AQSE-listed company whose ambition is to be a
leading provider of cannabinoid-based medicines for the treatment
of complex, chronic inflammatory pain conditions.
For more information, please visit:
https://anandadevelopments.com/
Market Abuse Regulation (MAR) Disclosure
The information contained within this announcement is deemed by
the Company to constitute inside information. Upon the publication
of this announcement via a Regulatory Information Service, this
inside information is now considered to be in the public
domain.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXEZLFFXVLZBBZ
(END) Dow Jones Newswires
August 15, 2023 02:00 ET (06:00 GMT)
Ananda Developments (AQSE:ANA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ananda Developments (AQSE:ANA)
Historical Stock Chart
From Jul 2023 to Jul 2024